Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 411

1.

Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial.

Collins ED, Kleber HD, Whittington RA, Heitler NE.

JAMA. 2005 Aug 24;294(8):903-13.

PMID:
16118380
2.

Three methods of opioid detoxification in a primary care setting. A randomized trial.

O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ.

Ann Intern Med. 1997 Oct 1;127(7):526-30.

PMID:
9313020
3.

Naltrexone shortened opioid detoxification with buprenorphine.

Umbricht A, Montoya ID, Hoover DR, Demuth KL, Chiang CT, Preston KL.

Drug Alcohol Depend. 1999 Oct 1;56(3):181-90.

PMID:
10529020
4.

Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.

Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, Brooklyn J.

Arch Gen Psychiatry. 2005 Oct;62(10):1157-64.

PMID:
16203961
5.

Heroin detoxification.

Favrat B, Besson J.

JAMA. 2006 Feb 22;295(8):885; author reply 886. No abstract available.

PMID:
16493096
6.

Heroin detoxification.

Miller MM.

JAMA. 2006 Feb 22;295(8):885-6; author reply 886. No abstract available.

PMID:
16493095
7.

Methods of detoxification and their role in treating patients with opioid dependence.

O'Connor PG.

JAMA. 2005 Aug 24;294(8):961-3. No abstract available.

PMID:
16118388
8.

Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.

Dunn KE, Tompkins DA, Bigelow GE, Strain EC.

JAMA Psychiatry. 2017 Sep 1;74(9):885-893. doi: 10.1001/jamapsychiatry.2017.1838.

PMID:
28700791
9.
10.

Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence.

Ziedonis DM, Amass L, Steinberg M, Woody G, Krejci J, Annon JJ, Cohen AJ, Waite-O'Brien N, Stine SM, McCarty D, Reid MS, Brown LS Jr, Maslansky R, Winhusen T, Babcock D, Brigham G, Muir J, Orr D, Buchan BJ, Horton T, Ling W.

Drug Alcohol Depend. 2009 Jan 1;99(1-3):28-36. doi: 10.1016/j.drugalcdep.2008.06.016. Epub 2008 Sep 20.

11.

A pilot study of naltrexone-accelerated detoxification in opioid dependence.

Bell JR, Young MR, Masterman SC, Morris A, Mattick RP, Bammer G.

Med J Aust. 1999 Jul 5;171(1):26-30.

PMID:
10451668
12.

Detoxification and treating opioid dependence.

de Jong CJ.

JAMA. 2006 Feb 22;295(8):887; author reply 887-8. No abstract available.

PMID:
16493098
13.

Opioid antagonists with minimal sedation for opioid withdrawal.

Gowing L, Ali R, White JM.

Cochrane Database Syst Rev. 2017 May 29;5:CD002021. doi: 10.1002/14651858.CD002021.pub4. Review.

PMID:
28553701
14.

Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial.

Schottenfeld RS, Chawarski MC, Mazlan M.

Lancet. 2008 Jun 28;371(9631):2192-200. doi: 10.1016/S0140-6736(08)60954-X.

15.

Buprenorphine for managing opioid withdrawal.

Gowing L, Ali R, White JM, Mbewe D.

Cochrane Database Syst Rev. 2017 Feb 21;2:CD002025. doi: 10.1002/14651858.CD002025.pub5. Review.

PMID:
28220474
16.

Opioid antagonist detoxification under anaesthesia versus traditional clonidine detoxification combined with an additional week of psychosocial support: a randomised clinical trial.

Favrat B, Zimmermann G, Zullino D, Krenz S, Dorogy F, Muller J, Zwahlen A, Broers B, Besson J.

Drug Alcohol Depend. 2006 Feb 1;81(2):109-16. Epub 2005 Jul 15.

PMID:
16024184
17.

An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.

Rothman RB, Gorelick DA, Heishman SJ, Eichmiller PR, Hill BH, Norbeck J, Liberto JG.

J Subst Abuse Treat. 2000 Apr;18(3):277-81.

PMID:
10742642
18.

Naltrexone and buprenorphine combination in the treatment of opioid dependence.

Gerra G, Fantoma A, Zaimovic A.

J Psychopharmacol. 2006 Nov;20(6):806-14. Epub 2006 Jan 9.

PMID:
16401652
19.

Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.

Mannelli P, Wu LT, Peindl KS, Swartz MS, Woody GE.

Drug Alcohol Depend. 2014 May 1;138:83-8. doi: 10.1016/j.drugalcdep.2014.02.002. Epub 2014 Feb 15.

Supplemental Content

Support Center